Post Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
Post The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early Career Researchers from Leading Research Institutions
Post Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors, Novel CAR-Ts and the Microbiome’s Potential in Immunotherapy
Post The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment
Post The Parker Institute for Cancer Immunotherapy Trains the Next Generation of Scientific Leaders in Cancer Immunotherapy
Post Ute Dugan Joins the Parker Institute for Cancer Immunotherapy as Senior Vice President of Clinical Research
Post NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer